Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases.
Adalimumab
/ administration & dosage
Anti-Inflammatory Agents
/ administration & dosage
Cellulitis
/ drug therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Injections, Subcutaneous
Male
Scalp Dermatoses
/ drug therapy
Skin Diseases, Genetic
/ drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Young Adult
Asian
adalimumab
follicular occlusion tetrad
perifolliculitis capitis abscedens et suffodiens
tumor necrosis factor
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
29
03
2019
accepted:
02
06
2019
pubmed:
5
7
2019
medline:
14
11
2019
entrez:
5
7
2019
Statut:
ppublish
Résumé
Perifolliculitis capitis abscedens et suffodiens (PCAS) or dissecting cellulitis is a rare condition presenting deep follicular occlusions, follicular ruptures and follicular infections in the scalp area with unknown etiology, which consequently cause primary neutrophilic cicatricial alopecia by the repeated follicular inflammation. PCAS is categorized as one of the "follicular occlusion tetrad" along with hidradenitis suppurativa, acne conglobata and pilonidal cyst. In the pathogenesis of the follicular occlusion tetrad, the involvement of neutrophils and its activator tumor necrosis factor (TNF) have been discussed. Here, we report a case of PCAS that was successfully treated with adalimumab, a human anti-TNF monoclonal antibody. This is the first Asian case of PCAS that was improved by a TNF inhibitor.
Identifiants
pubmed: 31271451
doi: 10.1111/1346-8138.14998
doi:
Substances chimiques
Anti-Inflammatory Agents
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Adalimumab
FYS6T7F842
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
802-807Informations de copyright
© 2019 Japanese Dermatological Association.
Références
Wise F, Parkhurst HJ. A rare form of suppurating and cicatrizing disease of the scalp: (perifolliculitis capitis abscedens et suffodiens). Arch Derm Syphilol 1921; 4: 750-768.
Martin R, Rullán JM. Refractory dissecting cellulitis of the scalp successfully controlled with adalimumab. P R Health Sci J 2015; 34: 102-104.
Badaoui A, Reygagne P, Cavelier-Balloy B et al. Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature. Br J Dermatol 2016; 174: 421-423.
Alikhan A, Sayed C, Alavi A et al. North American Clinical Management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 2019; 81: 76-90.
Ingram JR, Collier F, Brown D et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 2019; 180: 1009.
Sjerobabski Masnec I, Franceschi N. Perifolliculitis capitis abscedens et suffodiens treated with anti-tumor necrosis factor-alpha - possible new treatment option. Acta Dermatovenerol Croat 2018; 26: 255-289.
Mansouri Y, Martin-Clavijo A, Newsome P et al. Dissecting cellulitis of the scalp treated with tumour necrosis factor-α inhibitors: experience with two agents. Br J Dermatol 2016; 174: 916-918.
Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory dissecting cellulitis of the scalp treated with adalimumab. J Drugs Dermatol 2008; 7: 981-983.
Brandt HR, Malheiros AP, Teixeira MG et al. Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab. Br J Dermatol 2008; 159: 506-507.
Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol 2010; 146: 517-520.
Wollina U, Gemmeke A, Koch A. Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist. J Clin Aesthet Dermatol 2012; 5: 36.
Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther 2015; 28: 158-165.
Ralf Paus L, Kurzen H, Kurokawa I et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17: 455-456.
Van der Zee HH, de Ruiter L, Van Den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298.
Savva A, Kanni T, Damoraki G et al. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 2013; 168: 311-317.